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ABSTRACT
Previous studies reported the ability of raloxifene to acutely
relax arterial and venous vessels, but the underlying mecha-
nisms are controversial. Anti-inflammatory effects of the drug
have been reported in nonvascular tissues. Therefore, the aim
of this study was to investigate the nature of short- and long-
term effects of raloxifene on selected aspects of vascular func-
tion in rat aorta. Isometric tension changes in response to
raloxifene were recorded in aortic rings from ovariectomized
female rats that underwent estrogen replacement, whereas
long-term experiments were performed in isolated aortic
smooth muscle cells (SMCs). Raloxifene (0.1 pM–0.1 M) in-
duced acute vasorelaxation through endothelium- and nitric
oxide (NO)-dependent, prostanoid-independent mechanisms.
The relaxant response to raloxifene was significantly weaker
than that to 17-estradiol and was sensitive to neither the
nonselective estrogen receptor antagonist ICI 182,780 [7,17-
[9[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-
triene-3,17-diol] nor a selective estrogen receptor (ER)  antag-
onist. This rapid vasorelaxant effect was retained in aortic rings
from rats treated with 0.1 mg/kg, but not 1 mg/kg, lipopolysac-
charide, 4 h before sacrifice. In cultured aortic SMCs, raloxifene
treatment (1 nM–1 M) for 24 h reduced inducible NO synthase
activation in response to cytokines. This effect was prevented
by the selective ER antagonist and was associated with up-
regulation of ER protein levels, which dropped markedly upon
cytokine stimulation. These findings illustrate the relevance of
classic ER-dependent pathways to the vascular anti-inflamma-
tory effects rather than to the nongenomic vasorelaxation in-
duced by raloxifene and may assist in the design of novel ER
isoform-selective estrogen-receptor modulators targeted to the
vascular system.
Raloxifene is a selective estrogen-receptor modulator
(SERM) approved for use in osteoporosis and has been sug-
gested to be cardioprotective in women at high risk for coro-
nary heart disease (Barrett-Connor et al., 2002), although
these results were from post hoc analyses. In fact, the results
of the recently completed RUTH (Raloxifene Use for The
Heart) study indicate that treatment with raloxifene does not
significantly affect the risk of coronary events in postmeno-
pausal women at risk for coronary disease (Barrett-Connor et
al., 2006). Thus, a more detailed understanding of raloxifene
pharmacological action in vascular tissues is required to bet-
ter define and unravel potential benefits of treatment with
raloxifene and other SERMs.
A certain number of studies have examined the direct
effects of raloxifene on the vessel wall. It has been consis-
tently shown that the drug acutely relaxes different arterial
(Figtree et al., 1999; Tsang et al., 2004; Chan et al., 2005;
Leung et al., 2005) and venous (Bracamonte et al., 2002;
Chan et al., 2005) vessels from different animal species. A
variety of underlying mechanisms, however, can be involved,
including enhanced endothelial NO production (Figtree et
al., 1999; Bracamonte et al., 2002) and/or inhibition of L-type
voltage-sensitive Ca2 channels (Tsang et al., 2004; Chan et
al., 2005). Although long-term in vitro (Wassmann et al.,
2002) and in vivo (Rahimian et al., 2002) studies have con-
firmed the increased bioavailability of NO afforded by ralox-
ifene, several variables including gender, endothelial status,
vessel type, and animal species appear to affect treatment
outcomes. For instance, ovarian status is a general variabil-
ity source to be taken into account when exploring the vas-
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cular responses to estrogenic compounds (Bracamonte et al.,
2002; Bolego et al., 2005). The contribution of ER isoforms to
raloxifene-induced acute vascular relaxation as shown in the
above studies is also controversial. Both ER and ER are
expressed in rat aortic smooth muscle cells (SMCs) (Zancan
et al., 1999; Maggi et al., 2003), and recent work from our
group demonstrates a beneficial role for ER in the acute
vascular effects of estrogenic compounds (Bolego et al., 2005).
So far, there is no information as to the involvement of
specific ER isoforms in the vascular effects of raloxifene.
Beyond the modulation of vascular tone, there have been
recent indications that raloxifene is capable of decreasing
acute inflammation induced by lipopolysaccharide (LPS) in
microglial cells (Suuronen et al., 2005) and by carrageenan in
normal and ovariectomized rats (Esposito et al., 2005), but
the relevance of these findings to the cardiovascular system
is at present unknown.
Therefore, we investigated the vascular effects of ralox-
ifene, yet untested in rat aorta, using a dual approach. First,
acute vasomotor effects were tested on aortic rings from
estrogen-replaced ovariectomized rats to avoid fluctuations
in circulating hormones as seen in gonadally intact females.
Second, experiments were performed in isolated aortic SMCs
to test potential anti-inflammatory effects following long-
term treatment. The role of ER in raloxifene vascular action
was assessed using both the established ER antagonist ICI
182,780 and the newly described selective ER antagonist
MPP (Sun et al., 2002). ICI 182,780 is a high-affinity ER
antagonist (IC50  0.29 nM; Wakeling et al., 1991). MPP is a
selective, high-affinity silent antagonist at ER receptors
and displays 200-fold selectivity for ER over ER. Ki val-
ues are 2.7 and 1800 nM at ER and ER receptors, respec-
tively (Sun et al., 2002).
Methods and Materials
Drugs and Chemicals. Noradrenaline (NA) bitartrate, acetyl-
choline chloride, NG-nitro-L-arginine methyl ester (L-NAME), LPS,
and 17-estradiol (E2) were purchased from Sigma Chemical (Milan,
Italy). The estrogen receptor antagonists ICI 182,780 and MPP were
purchased from Tocris Cookson Inc. (Bristol, UK). Raloxifene was
kindly provided by Eli Lilly and Co. (Indianapolis, IN). The anti-
inducible NO synthase (iNOS) polyclonal antibody was purchased
from BD Biosciences Transduction Laboratories (Lexington, KY), the
anti-ER antibody was from Santa Cruz (Santa Cruz, CA), and the
peroxidase-coupled secondary antibody was obtained from Vector
(Burlingame, CA). For organ bath experiments, raloxifene was dis-
solved in 2-hydroxypropyl--cyclodextrin (Sigma) because dimethyl
sulfoxide as a vehicle affected the tone of precontracted aortic rings
as assessed in preliminary experiments (data not shown). The cyclo-
dextrin percentage in the tissue bath did not exceed 0,1%. E2 and ICI
182,780 were dissolved in ethanol, whose final concentration in the
tissue bath did not exceed 0.01%.
Animals. Female Sprague-Dawley rats weighing 200 to 250 g
(Charles River Italia, Calco, Italy) were kept in temperature-con-
trolled facilities on a 12-h light/dark cycle and fed normal chow.
Bilateral ovariectomy was performed under ketamine (40 mg/kg i.p.)
and xylazine (20 mg/kg i.p.) anesthesia. Four weeks later, animals
were implanted two silastic capsules containing 25 l of vehicle
(peanut oil) or E2 (5.87 g; 0.86 mM) for 5 days (Bolego et al., 1999;
Cignarella et al., 2000). Plasma E2 concentrations after this treat-
ment approached the normal rat proestrus level (Lapchak, 1991).
This procedure aimed at bypassing estrus cycle-associated variations
in vasomotor responses. All procedures conformed to the Guidelines
for the Care and Use of Laboratory Animals (National Institutes of
Health Publication 85-23, revised 1996).
Isometric Tension Recording Experiments. Vessel prepara-
tions were obtained as described previously (Bolego et al., 2005). In
brief, 5- to 6-mm aortic rings were suspended in 5-ml organ baths
containing Krebs’ solution at 37°C. The Krebs’ solution had the
following composition: 118 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4,
1.1 mM MgSO4, 2.5 mM CaCl2, 25 mM NaHCO3, and 5.5 mM
glucose, pH 7.4. The rings were connected to isometric tension trans-
ducers (Fort 10; World Precision Instruments, Sarasota, FL) coupled
with a digital recording system (PowerLab 8SP; AD Instruments,
Basile, Comerio, Italy), equilibrated for 30 min, and contracted with
105 M NA to evoke a maximal response. Preparations were then
washed with fresh Krebs’ solution, and the equilibration period was
allowed to continue for a further 30 min. Experiments were carried
out on tissues precontracted with NA to 60% of maximal contraction
(EC60  10
7 M). The endothelium was considered functional when
relaxation of precontracted vessels to 105 M acetylcholine was at
least 80%. Care was taken to distinguish drug-induced reduction in
tone versus loss of tone over time. To test drug vehicle effects,
cumulative additions of equivalent solvent dilutions were performed.
Responses were expressed as percentage of relaxation from NA-
induced contraction.
In Vivo LPS Treatment. Following ovariectomy and E2 capsule
implantation, animals were injected i.p. with LPS (0.1 or 1 mg/kg) or
saline. At 4 h after injection, when fever reached a plateau and
induction of vascular inflammatory enzymes was maximal (Cao et
al., 1995; Sunday et al., 2006), the aorta was excised, and aortic rings
Fig. 1. A, concentration-response curves of aortic
rings from E2-replaced ovariectomized female rats
precontracted with 0.1 M noradrenaline and incu-
bated with raloxifene (full squares) and E2 (trian-
gles). The vehicle curve (cyclodextrin, empty
squares) is shown as well. Statistical analysis for
the two agonists’ curves relates to the concentration
range of up to 0.1 M. n 5 to 7, p 0.001 (two-way
ANOVA). B, before generating curves as shown in A,
a concentration-response curve to Ach was obtained
(control, circle). In all three groups, Ach relaxation
was attained with similar efficiency after the high-
est concentration of raloxifene, E2, and vehicle to
demonstrate a functional endothelium. n  3.
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were mounted in organ baths to obtain concentration-response
curves to raloxifene as described above.
Cell Culture. SMCs obtained from aortic intimal-medial layers of
male Sprague-Dawley rats expressed ER (Zancan et al., 1999; Maggi
et al., 2003). These SMCs were used not later than the fifth passage
and seeded in six-well plates (3  105 cells/well) for experiments. On
reaching approximately 70% confluence, the medium was replaced
with phenol red-free M199 with 10% FCS for 2 days. SMCs were then
synchronized in medium containing 0.4% FCS for 24 h and incubated
for a further 24 h with a cytokine mixture comprising 10 ng/ml
interleukin-1, 10 ng/ml interferon-, and 25 ng/ml tumor necrosis
factor- plus 1 g/ml LPS. Such a mixture, which is likely to occur in
vivo in settings of vascular inflammation, consistently induced iNOS
protein formation in SMCs (Zancan et al., 1999). Raloxifene (dis-
solved in dimethyl sulfoxide) was added at the same time as cyto-
kines where indicated, whereas MPP was added 30 min before.
Cell Viability Assay. Once 5  103 or 8  103 cells/well were
plated in a 96-well plate, they were first incubated for 24 h in M199
with 10% FCS and then switched to phenol red-free M199 with
10% FCS for 2 days and phenol red-free M199 with 0.4% FCS for
24 h. Cell viability was assessed after a 24-h incubation with the
LPS/cytokine mixture in the presence or absence of 1 M raloxifene.
The number of surviving cells was assessed as described elsewhere
(Takahashi et al., 2003) by recording the absorbance at 490 nm
generated by the bioreduction of the MTS tetrazolium compound into
a colored soluble formazan product (Cell Titer 96 AQueous One
Solution Cell Proliferation Assay; Promega, Madison, WI).
Western Blot Analysis. Cells were washed twice with phos-
phate-buffered saline and extracted directly into the lysis buffer as
described previously (Idel et al., 2002). At least 30 g of cell protein
was loaded onto 10% SDS-acrylamide gels. At the end of the run,
proteins were transferred onto Hybond-ECL membranes (GE
Healthcare, Little Chalfont, Buckinghamshire, UK). The blots were
incubated with the primary antibody (1:1000) overnight followed by
the peroxidase-conjugated secondary antibody for 1 h and, after
extensive washing, were developed by chemiluminescence. Sample
loading control was performed using -actin immunodetection.
Nitrite Assay. Culture medium was collected and centrifuged at
12,000 rpm for 5 min. Next, 250 l/well medium was treated with 20
l of 6.5 M HCl and 20 l of 37.5 mM sulfanilic acid in a 96-well
plate. After incubation for 10 min, 20 l of 12.5 mM N-(1-naphthyl)-
ethylendiamine was added. Optical density was read at 550 nm after
15 min. Nitrite values were expressed as micromoles of nitrite per
milligram of cell protein.
Statistical Analysis. All data were expressed as means S.E.M.
and represent unpaired data. Concentration-response curves were
obtained using the software Prism (GraphPad Software Inc., San
Diego, CA) and compared by means of two-way analysis of variance
(ANOVA) followed by a post hoc test. pD2 values and maximal
responses were compared by one-way ANOVA followed by Bonferro-
ni’s post hoc test, using the software Minitab (Minitab Inc., State
College, PA). Cell culture data were obtained from at least four
independent experiments, each value representing mean S.E.M. of
duplicate or triplicate determinations. Statistical evaluation was
performed using unpaired Student’s t test or one-way ANOVA with
Fisher analysis when more than two groups were compared. Values
of p  0.05 were considered significant.
Results
Raloxifene induced acute concentration-dependent relax-
ation of endothelium-intact NA-precontracted aortic rings
from E2-replaced ovariectomized rats (Fig. 1A). In the con-
centration range of up to 0.1 M, which is likely to be rele-
vant in vivo, the maximal response was modest but signifi-
cant (15% relaxation). At higher concentrations, the
magnitude of raloxifene-induced relaxation sharply in-
creased starting at 10 M and approaching 70% at 100 M.
Cyclodextrin solvent controls had no effect on vascular tone.
As shown in Fig. 1A, raloxifene was significantly less potent
and effective than E2 at relaxing precontracted aortic rings
(pD2, 9.9  0.4 versus 10.4  0.3; Emax, 13.4  1.1% versus
23.3  2.1%; n  5–7, p  0.001). As shown in Fig. 1B,
acetylcholine (Ach) relaxation was attained with similar ef-
ficiency in the three groups both prior to generating curves
and after the highest agonist concentration to demonstrate
that the endothelium was functional throughout the experi-
ment.
Fig. 2. Concentration-response curves of aortic rings from 17-estradiol-
replaced ovariectomized female rats precontracted with 0.1 Mnoradren-
aline and incubated with raloxifene alone (squares), in the presence of the
NO synthase inhibitor L-NAME (3 M; triangles) or the cyclooxygenase
inhibitor indomethacin (1 M; diamonds) and in the absence of endothe-
lium (circles). Emax L-NAME and Emax no endothelium, p  0.001 versus
raloxifene; Emax indomethacin, N.S.; n  5, two-way ANOVA.
Fig. 3. A, concentration-response curves of aortic rings
from 17-estradiol-replaced ovariectomized rats precon-
tracted with 0.1 M noradrenaline and incubated with
raloxifene in the absence (squares) or presence of the an-
tiestrogen ICI 182,780 (1 M, triangles) and the selective
ER antagonist MPP (10 M; circles). The three curves are
not statistically different. B, concentration-response curves
of aortic rings from 17-estradiol-replaced ovariectomized
rats precontracted with 0.1 M noradrenaline and incu-
bated with 17-estradiol alone (triangles) or in the pres-
ence of the selective ER antagonist MPP (10 M; circles).
A, n  4, N.S.; B, n  5, p  0.001 versus vehicle (two-way
ANOVA).
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Raloxifene-induced relaxation of precontracted aortic rings
was virtually abolished by incubation with 3 M L-NAME
and by endothelium removal (Fig. 2), as previously shown in
different vascular beds (Figtree et al., 1999; Bracamonte et
al., 2002). To determine whether raloxifene-induced vasodi-
latation was related to any extent to prostanoid release,
inhibiting cyclooxygenase with indomethacin (1 M) had no
effect on relaxations to raloxifene in aortic rings with endo-
thelium (Fig. 2; Emax L-NAME, 5.6  2.0%, n  4, p  0.001
versus raloxifene; Emax no endothelium, 3.7  0.6%, n  3,
p 0.001 versus raloxifene; Emax indomethacin, 14.5 1.7%,
n  5, N.S.).
When testing the role of ER in raloxifene-induced acute
relaxation of aortic tissues, pretreatment with ICI 182,780 (1
M) failed to affect the response (Fig. 3A; pD2, 9.9  0.7
versus 10.0  0.3; Emax, 13.4  1.1% versus 16.8  2.7%, n 
7, N.S.). The same was true when tissues were preincubated
with the selective ER antagonist MPP (10 M; Fig. 3A; pD2
MPP, 10.0  0.5, n  4, N.S.). In contrast, this selective
antagonist significantly impaired E2-evoked vasodilator re-
sponses (Fig. 3B; pD2 MPP, 9.8  1.3 versus 10.4  0.3, n 
5, p  0.001), suggesting that the pharmacological action
profiles of raloxifene and E2 do not fully overlap.
The reported decrease in inflammatory responses after
raloxifene treatment in vitro and in vivo (Esposito et al.,
2005; Suuronen et al., 2005) led us to test potential anti-
inflammatory effects of the drug in the vessel wall. Therefore,
the effect of raloxifene on vascular tone was investigated in
ex vivo aorta from rats under inflammatory challenge. As
shown in Table 1, raloxifene retained its relaxant activity in
aortic rings isolated from rats treated with 0.1 mg/kg LPS
Fig. 4. Effects of raloxifene and the estrogen receptor- antagonist MPP on cytokine-induced iNOS protein synthesis (A and B) and activity (C and
D) in rat aortic smooth muscle cells. Cells were grown in phenol red-free M199 medium for 2 days, synchronized in 0.4% FCS for 24 h, and stimulated
with a cytokine cocktail (10 ng/ml interleukin-1, 10 ng/ml interferon-, 25 ng/ml tumor necrosis factor- plus 1 g/ml LPS) for 24 h. Increasing
concentrations of raloxifene (1 nM–1 M) were added where indicated at the same time as cytokines in the absence (A and C) or presence (B and D)
of 1 MMPP added 30 min before. The amount of iNOS in cell lysates was measured by scanning densitometry, whereby the intensity of the cytomix
band was set arbitrarily to 100. Representative Western blots are shown. The culture media were harvested and samples thereof assayed for nitrite
accumulation using the Griess reaction. Data are expressed as means  S.E.M. of four to eight independent experiments. , p  0.05 compared with
cytokines alone, ANOVA.
TABLE 1
Rapid effects of raloxifene on the relaxation of precontracted aortic
rings from estrogen-replaced ovariectomized rats under inflammatory
challenge
E2-replaced ovariectomized rats were treated with 0.1 or 1 mg/kg LPS for 4 h before
sacrifice. Tension recording experiments in response to raloxifene were performed as
described under Materials and Methods. Results indicate the percent relaxation of
NA-precontracted tone and are expressed as mean of S.E.M. (n 3 for each group).
Raloxifene
LPS
0 0.1 1
log M mg/kg
11 1.9  1.5 3.0  1.9 3.3  0.8
9 8.6  1.5 10.1  4.2 3.9  2.4
7 12.4  1.0 13.4  3.5 4.6  2.0
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but not from those treated with 1 mg/kg LPS 4 h before
sacrifice.
The possibility that raloxifene could also modulate vascu-
lar function through long-term effects was investigated in
isolated SMCs from rat aorta. After stimulation with cyto-
kine plus LPS mix for 24 h, iNOS became detectable in aortic
SMCs (Fig. 4A). This cytokine-elicited rise in iNOS protein,
however, was significantly attenuated by incubation with 0.1
and 1 M raloxifene (Fig. 4A). As shown in Fig. 4B, this effect
was mediated by ER because MPP pretreatment blocked
raloxifene action on iNOS protein over 24 h. Neither ralox-
ifene nor MPP promoted iNOS synthesis in the absence of
cytokines (data not shown). Raloxifene treatment for 24 h
significantly decreased cytokine-stimulated iNOS activity, as
measured by nitrite accumulation in the culture medium
(Fig. 4C), at the highest concentration tested of 1 M (p 
0.05). This effect was again abolished by preincubation with
MPP (Fig. 4D). Under the same experimental conditions,
raloxifene treatment failed to affect the functional expression
of cyclooxygenase-2, another molecular target indicative for
vascular inflammation (data not shown). The observed reduc-
tion in iNOS expression and activity was not merely the
result of cell death because no significant growth inhibitory
effect by raloxifene treatment at 1 M was observed after
24 h in SMCs plated at two different initial density values
(5  103 and 8  103 cells/well) (Fig. 5).
Based on the above findings, the negative regulation of
iNOS functional expression induced by raloxifene treatment
appeared to be mediated by ER. Hence, we investigated if
the drug had any influence on ER protein formation over
the course of the anti-inflammatory action. In agreement
with previous studies (Maggi et al., 2003), the cytokine/LPS
mixture reduced the amount of immunodetectable ER by
approximately 70% in vascular SMCs (Fig. 6A). Yet, treat-
ment with increasing concentrations of raloxifene partially
restored ER protein levels under these experimental condi-
tions (Fig. 6A). In a different set of experiments, preincuba-
tion with MPP at 10 M but not 1 M was found to prevent
the rise in ERmediated by raloxifene while being ineffective
when added alone (Fig. 6B). This suggests that raloxifene is
capable of interacting with and regulating the amount of
ER.
Discussion
The present study describes novel aspects of the vascular
pharmacology of raloxifene. We herein report a nongenomic
vasorelaxant effect in aortic rings from female rats with
steady estrogen concentrations, thereby ruling out the con-
founding factors of estral cycle and hormone deprivation; the
maintenance of this rapid effect in aortic preparations ex vivo
from animals under inflammatory challenge; and an anti-
inflammatory action in isolated aortic SMCs. The last two
effects, to the best of our knowledge, have not been described
before. The present findings confirm that raloxifene has the
potential to reproduce selected genomic and, to a lesser ex-
tent, nongenomic actions of E2 in the vascular wall. Distinct
mechanisms account for the nongenomic as opposed to long-
term effects of raloxifene. In particular, the involvement of
classic ERs in raloxifene action was not apparent for the
nongenomic vasorelaxant effect but could be shown for the
long-term anti-inflammatory action, indicating that multiple
mechanisms of action drive raloxifene action in the arterial
wall as depicted in Fig. 7. The therapeutic relevance of these
findings needs to be determined in further studies, but ex-
Fig. 5. Raloxifene does not affect the viability of rat aortic smooth muscle
cells under inflammatory challenge. Cells were seeded at 5000 or 8000/
well in a 96-well plate and cultured in M199 medium plus 10% FCS for
24 h. Thereafter, cells were treated as described in the legend to Fig. 4.
After the final 24-h incubation, cell viability was evaluated by the MTS
assay after 1.5 to 3 h as described under Materials and Methods. Cell
growth is expressed as the relative absorbance obtained in the control
condition. Data are expressed as means  S.E.M. of three independent
experiments, each with n  8 to 24 in all groups.
Fig. 6. Concentration-dependent ef-
fect of raloxifene (A) and modulation
by the selective antagonist MPP (B)
on the accumulation of estrogen re-
ceptor- protein in rat aortic smooth
muscle cells stimulated with a cyto-
kine/LPS mixture for 24 h. Cell incu-
bation and Western blotting proce-
dures were as described in the legend
to Fig. 4. Data are expressed as
means  S.E.M. of six (A) or four (B)
independent experiments. , p  0.01
compared with basal, Student’s t test;
#, p  0.05 compared with cytokines
alone, ANOVA; §, p  0.05 compared
with raloxifene alone, one-way
ANOVA.
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periments in the present work were performed at raloxifene
concentrations not too distant from possible peak plasma
concentrations in women after long-term oral administration
(Morello et al., 2003).
In agreement with previous studies in rabbit coronary
arteries (Figtree et al., 1999) and pig femoral veins (Bra-
camonte et al., 2002), raloxifene-induced acute relaxation of
rat aortic rings was endothelium- and NO-dependent. This
finding, however, was not confirmed in rat cerebral (Tsang et
al., 2004) or intrarenal arteries (Leung et al., 2005) and
pulmonary vessels (Chan et al., 2005), wherein the relaxant
effect has been attributed primarily to inhibition of voltage-
sensitive Ca2 channels. Therefore, the nature of this rapid
effect of raloxifene is controversial. In fact, gender, endothe-
lial status, precontracting agent, and regional distribution of
molecular targets (ER, ion channels) may sway the onset of
different pathways in response to raloxifene treatment. Evi-
dence suggests that raloxifene is capable of evoking vascular
relaxation via both endothelium-dependent and -indepen-
dent pathways, which may not be mutually exclusive though.
Accordingly, our data suggest two components of action of
raloxifene (Fig. 1), which were also able to markedly relax
endothelium-denuded aortic rings at pharmacological con-
centrations above 10 M (data not shown). Although the
latter effect is consistent with inhibition of Ca2 channels,
acute relaxant responses to estrogen-related agents at sub-
micromolar concentrations may be secondary to activation of
ER located on the plasma membrane and downstream up-
regulation of endothelial NO synthase (Chen et al., 1999;
Kim et al., 1999). Our results only partially fit with this
paradigm because neither ICI 182,780 nor the selective ER
antagonist MPP affected the acute relaxant response to
raloxifene. To reconcile these conflicting results, it may be
assumed that raloxifene bound to a novel membrane SERM
receptor (Mercier et al., 2003) or that ER antagonists inhib-
ited only specific components of raloxifene action. In fact,
endothelium-dependent relaxation to tamoxifen is only par-
tially inhibited by ICI 182,780 (Figtree et al., 2000). In other
studies, ICI 182,780 failed to block all responses mediated by
estrogenic compounds (Dudley et al., 2000). It is also conceiv-
able that ICI 182,780 and MPP are effective antagonists of
full-length ER but not of such truncated variants thereof
expressed in rats as the splice variant ER46 (Longo et al.,
2004; Staub et al., 2005), which might still be activated by
raloxifene leading to increased endothelial NOS function
(Haynes et al., 2000). The mechanisms of raloxifene-medi-
ated acute vasorelaxation, however, did differ from those of
E2 under our experimental conditions (Fig. 7) because the
latter was significantly more effective and more potent than
the former (Fig. 1) and was sensitive to antagonism by both
ICI 182,780 (Bolego et al., 2005) and MPP (Fig. 4). This
pattern may be further affected by gender and ovarian status
(Bracamonte et al., 2002; Bolego et al., 2005), but E2 replace-
ment to ovariectomized rats as used in the present study
rules out the confounding variables of estrus cycle and hor-
mone deprivation.
The duration of exposure to raloxifene as well as other
estrogenic compounds is a critical determinant of activation
of different mechanisms in reproductive tissues (Zheng et al.,
2004). Therefore, short-term nongenomic effects of raloxifene
as discussed above may be associated with long-term
genomic effects in the vessel wall. On testing this hypothesis,
we detected novel anti-inflammatory properties of raloxifene
in isolated vascular SMCs in culture, consistent with those
shown in microglial cells (Suuronen et al., 2005) and on
carrageenan-induced paw edema and pleurisy after in vivo
treatment (Esposito et al., 2005). In addition, the present
study reports that the rapid vasorelaxation mediated by
raloxifene was retained in aortic tissues from rats under
moderate inflammatory challenge as induced by low-dose
LPS. By contrast, no effect of raloxifene on vascular tone was
detected in tissues from animals challenged with high-dose
LPS, possibly because of a massive systemic vascular NO
release (Vo et al., 2005) that outweighed the acute release
triggered by the drug in the organ bath. To allow more
predictive conclusions on the relevance of these mechanisms,
further studies with long-term raloxifene treatment should
be performed using in vivo models of vascular inflammation.
At the cellular level, the decrease in iNOS functional ex-
pression induced by raloxifene after 24-h treatment (Fig. 4A)
resembles that induced by E2 in vascular SMCs (Zancan et
al., 1999). At variance with acute vasorelaxation, iNOS inhi-
bition by raloxifene was blocked by MPP, suggesting the
Fig. 7. Schematic diagram of the mechanism of regulation of vascular
tone and iNOS expression by raloxifene. At nanomolar concentrations,
both E2 and raloxifene (Ral) induce rapid L-arginine (L-Arg)-derived NO-
dependent vasorelaxation. Although it is established that E2 acts via
membrane ER by activating Akt and endothelial NOS (eNOS) phosphor-
ylation, a pathway that is blocked by selective or nonselective ER antag-
onists [ICI 182,780 (ICI), MPP], raloxifene-driven eNOS activation is
insensitive to ER antagonists and may occur through a different ER
domain or variant with respect to E2 or through a putative SERM recep-
tor. This acute vasorelaxant effect of raloxifene is retained after challenge
with 0.1 mg/kg LPS in vivo (not shown). At micromolar concentrations
(Ral), raloxifene may relax directly vascular smooth muscle cells by
modulating ion channels. Upon activation of inflammatory signaling
pathways, ER levels are decreased, and iNOS production is enhanced in
smooth muscle cells, leading to accumulation of NO as well as of harmful
derivatives thereof such as peroxynitrite. By acting through intracellular
ER, Ral restores, at least in part, ER protein levels and down-regulates
iNOS functional expression. Although the nature of the association be-
tween ER activation and iNOS function remains to be established, this
pathway does not involve direct transcriptional modulation because the
iNOS gene lacks estrogen response elements (data not shown). CaM,
calmodulin.
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onset of ER-dependent mechanisms. Raloxifene binds to
and activates ER and ER (Brzozowski et al., 1997;
Barkhem et al., 1998; Pike et al., 1999), both of which are
expressed in rat aortic SMCs (Zancan et al., 1999; Maggi et
al., 2003). ER contribution to the anti-inflammatory effect of
SERM in microglial cells has not been assessed, although the
authors argue that the SERM-induced response is due to
interference with the signaling cascade activated by LPS
treatment (Suuronen et al., 2005). To the best of our knowl-
edge, we here report for the first time that iNOS inhibition by
raloxifene was ER-dependent and was associated with up-
regulation of ER protein levels that had been decreased by
cytokine challenge (Fig. 6). This is an autologous regulation
pathway because it is inhibited by MPP and likely involves
binding of liganded ER to the ER gene (Barchiesi et al.,
2004), thus enhancing transcription at least when inflamma-
tory signaling pathways are operating (Fig. 7). Although the
relationship between ER protein expression and iNOS-me-
diated NO formation remains to be established, increased
concentrations of E2 also up-regulate ER in rat vascular
SMCs (Maggi et al., 2003). Thus, a potential amplification of
ER action occurs with prolonged ligand activation in vascu-
lar SMCs. These findings are also in agreement with the
anti-inflammatory role of ER as described in other tissues
(Evans et al., 2002; Vegeto et al., 2003) and instead hint at a
pro-inflammatory role for genomic ER activation in the
vascular wall as that induced, for instance, by the relatively
ER-selective phytoestrogen genistein (Cignarella et al.,
2006). This fits with the current paradigm of the yin/yang
relationship between the two cloned ER isoforms (Weihua et
al., 2003). Consequently, any shift in the relative ER expres-
sion pattern in vascular and other tissues may be potentially
associated with changes in the anti-inflammatory action of
estrogenic compounds.
In conclusion, raloxifene rapidly relaxed aortic tissues of
E2-replaced ovariectomized female rats also following inflam-
matory challenge and prevented cytokine-driven iNOS acti-
vation in isolated aortic SMCs after 24-h treatment. These
effects were raised at concentrations that may be relevant in
vivo and involved, at least in part, ER activation. This
combined action of raloxifene on vascular function could con-
tribute to explain its antiatherosclerotic properties in animal
models (Bjarnason et al., 2001) and may lay the ground for
the development of novel ER isoform-selective SERMs with
targeted action to the vascular system (Bolego et al., 2006).
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